Article
Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
International journal of clinical oncology - 1 Apr 2020
Taguchi Daiki, Inoue Masahiro, Fukuda Koji, Yoshida Taichi, Shimazu Kazuhiro, Fujita Kazuma, Okuyama Hiroyuki, Matsuhashi Nobuhisa, Tsuji Akihito, Yoshida Kazuhiro, Miura Masatomo, Shibata Hiroyuki
Abstract excerpt
BACKGROUND: Regorafenib is a multiple tyrosine kinase inhibitor, and the use of this drug is approved for the treatment of cancers that are resistant to chemotherapy, which include advanced colorectal cancer, gastrointestinal stromal tumor, and hepatocellular carcinoma. However, the drug causes adverse events, including skin toxicities that require dose modification in approximately 75% of cases. At present, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.